Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

The user is seeking advice on which hair growth oil to add to their current regimen of finasteride, Nizoral, and micro-needling. They are considering oils with ingredients like biotin, caffeine, castor oil, rosemary oil, hemp, coconut, olive, lavender, peppermint, aloe, horsetail, vitamin B5, rosehip seed, and algae.

Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

A user found that taking Zyrtec (Cetirizine) and Advil helped reduce their scalp inflammation and pain, potentially creating a better environment for hair growth. They have not used any other medication for hair loss or scalp issues.

The conversation discusses hair loss treatments, specifically Brassica oleracea extract, glucosinolates, and sulforaphane, and their potential to promote hair growth. Users also mention minoxidil and finasteride as existing treatments.

Blocking DHT is not a complete solution for hair loss; instead, altering the scalp's response to DHT may be more effective. Topical finasteride and minoxidil are current treatments, but future approaches may involve bioengineering, gene therapy, and inflammation control.

Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

KX-826 is being considered as a potential alternative to finasteride for hair loss, but it is not expected to be more effective. Combining KX-826 with finasteride and minoxidil may provide better results than using it alone.

The conversation is about enhancing dermarolling for hair loss by using topical peptides like tb-500 or GHK-Cu to aid in healing and hair growth, and whether anyone has experienced significant results from this method.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.